ACE2 News and Research

RSS

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A preprint discusses the results of a study of antibody responses to the first and second dose of currently available SARS-CoV-2 vaccines, Pfizer and Oxford.

19 May 2021

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

Researchers have reported the first case of COVID-19 triggering a rare occurrence of potentially severe blood clots forming in the arms.

19 May 2021

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

India’s surge in SARS-CoV-2 infections are linked to the new variants B.1.617 and B.1.618, with mutated spike proteins.

19 May 2021

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

In a new study posted to the bioRxiv* preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tissue culture – at concentrations of at least 100 times lower than required for cytotoxic effects.

19 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

In a new study, researchers used an antibody discovery technology to identify a new potently neutralizing antibody with a unique mode of SARS-CoV-2 recognition. They reported their results on the bioRxiv preprint server.

18 May 2021

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Researchers discovered the first N440K variant and the new E484Q and L452R Indian variants isolated in France in a recent study. They presented the genetic mutations in the isolated genomes and the phylogenetic tree, including these strains among different SARS-CoV-2 clades. This work is posted on the bioRxiv preprint server.

18 May 2021

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Researchers in the United States have demonstrated the long-term durability of the antibody responses elicited by Moderna’s mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 May 2021

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

A new research paper published in the journal Science explores the differences in coronavirus-specific B memory cell repertoires in children versus adults, as well as the functional importance of this discovery.

18 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

In a recently published research paper in the journal Nature Communications, a team of scientists from China has described the antiviral efficacy of a novel anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody isolated from recovered coronavirus disease 2019 (COVID-19) patients.

17 May 2021

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

The World Health Organization (WHO) has labeled the double mutant B.1.617 variant — first discovered in India —a variant of concern for its high transmission rate and ability to evade immune responses. New research posted to the preprint server bioRxiv finds B.1.617 can modestly reduce neutralizing antibody responses generated from the Pfizer-BioNTech vaccine.

16 May 2021

Supercarriers: Just 2% of SARS-CoV-2 positive people carry 90% of the virus

A new study published in the Proceedings of the National Academy of Sciences shows that the vast majority of the viral load in a community at any given point is present in a very small minority of the infected population, underlining the vast differences in viral loads between individuals.

14 May 2021

A look at how coronavirus disease (COVID-19) affects Parkinson's

Earlier, herpes simplex virus (HSV), influenza virus A, measles virus, cytomegalovirus (CMV), and mumps virus have all been associated with after-effects of the virus that includes Parkinson's disease (PD). This list may now include SARS-CoV-2.

14 May 2021

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

In a recent bioRxiv* preprint research paper, M. Gordon Joyce et al. designed engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion Spike (S), S1 and receptor-binding domain (RBD). They demonstrated that these immunogens induced robust S-binding, ACE2 (angiotensin-converting enzyme)-inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2 in mice.

13 May 2021

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating SARS-CoV-2 variants with multiple spike mutations.

13 May 2021

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

The importance of computational modeling in the prediction of the course of the ongoing COVID-19 pandemic, as well as evaluating multiple potential drug leads, has never been more clear. Now, a new study describes a set of designer vaccine antigens that may improve vaccine stability as well as enhance the neutralizing antibody response.

13 May 2021

ACE2 News and Research

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

Nanotechnology and COVID-19 diagnosis and treatment

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

Supercarriers: Just 2% of SARS-CoV-2 positive people carry 90% of the virus

A look at how coronavirus disease (COVID-19) affects Parkinson's

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

Inexpensive test for rapid detection of COVID-19 with 90% accuracy

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News